29.10.2010 • NewsDowQ3 2010

Dow Chemical Q3 Profit Beats, Shares Up

Dow Chemical posted a better-than-expected quarterly profit due to strong sales of chlorine, basic plastic and lubricants, sending shares up 1.5% in early trading.

The results reflect improving consumer demand for a wide range of products made using Dow materials, especially in North America and Europe, where the company had been weak in recent quarters.

Dow Chief Executive Andrew Liveris said he sees "a sustained global economic recovery, led by emerging economies," adding he is bullish on growth in Brazil, Eastern Europe and the Middle East.

The company reported net income of $512 million, or 45 cents per share, compared with $711 million, or 63 cents per share, a year earlier.

Excluding one-time items, Dow earned 54 cents per share. By that measure, analysts had expected earnings of 41 cents per share, according to Thomson Reuters I/B/E/S.

The one-time items include a $35 million charge to further integrate Rohm & Haas, a rival specialty chemicals maker Dow bought in April 2009.

Revenue at the Midland, Mich.-based company rose 6.8% to $12.87 billion. Analysts had expected $12.81 billion.

Volume rose 14% while pricing increased 9%, offsetting higher raw material costs, Dow said.

Dow rival DuPont Co posted a higher-than-expected quarterly profit and raised its 2010 earnings forecast on Tuesday.

 

Company

The Dow Chemical Company

100 Larkin Center
48674 Midland

Company contact







Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.